Spanish biotech Tetraneuron raises more than 2.5 million euros to advance its Alzheimer’s therapy

The biotech company is developing an innovative therapy based on a multifactorial approach to Alzheimer's disease with the potential to slow the progression of the disease. Supported by good preclinical data, Tetraneuron will advance in the regulatory roadmap.